Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone A Huygens

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Multiple Sclerosis and Related Disorders|July 27, 2025
Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribineMatthijs M Versteegh, Simone A Huygens
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple SclerosisMatthijs M Versteegh, Simone A Huygens, Beatrijs W H Wokke, et al.
Pharmacoeconomics|February 19, 2021
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of VisionSimone A Huygens, Matthijs M Versteegh, Stefan Vegter, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 8, 2017
Systematic review of model-based economic evaluations of heart valve implantationsSimone A Huygens, Johanna J M Takkenberg, Maureen P M H Rutten-van Mölken
Molecular Diagnosis & Therapy|April 14, 2024
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The NetherlandsIrene Santi, Heleen Vellekoop, Matthijs M Versteegh, et al.
Multiple Sclerosis and Related Disorders|November 9, 2023
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence modelCato E A Corsten, Simone A Huygens, Matthijs M Versteegh, et al.
Pharmacoeconomics|August 23, 2025
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's DiseaseMatthijs M Versteegh, Simone A Huygens, Inigo Bermejo, et al.
Open Heart|March 14, 2018
How much does a heart valve implantation cost and what are the health care costs afterwards?Simone A Huygens, Lucas M A Goossens, Judith A van Erkelens, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 22, 2024
How microsimulation translates outcome estimates to patient lifetime event occurrence in the setting of heart valve diseaseMaximiliaan L Notenboom, Reda Rhellab, Jonathan R G Etnel, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 30, 2018
Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity†Simone A Huygens, Frank van der Kley, Jos A Bekkers, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis and Related Disorders|July 27, 2025
Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribineMatthijs M Versteegh, Simone A Huygens
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple SclerosisMatthijs M Versteegh, Simone A Huygens, Beatrijs W H Wokke, et al.
Pharmacoeconomics|February 19, 2021
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of VisionSimone A Huygens, Matthijs M Versteegh, Stefan Vegter, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 8, 2017
Systematic review of model-based economic evaluations of heart valve implantationsSimone A Huygens, Johanna J M Takkenberg, Maureen P M H Rutten-van Mölken
Molecular Diagnosis & Therapy|April 14, 2024
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The NetherlandsIrene Santi, Heleen Vellekoop, Matthijs M Versteegh, et al.
Multiple Sclerosis and Related Disorders|November 9, 2023
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence modelCato E A Corsten, Simone A Huygens, Matthijs M Versteegh, et al.
Pharmacoeconomics|August 23, 2025
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's DiseaseMatthijs M Versteegh, Simone A Huygens, Inigo Bermejo, et al.
Open Heart|March 14, 2018
How much does a heart valve implantation cost and what are the health care costs afterwards?Simone A Huygens, Lucas M A Goossens, Judith A van Erkelens, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 22, 2024
How microsimulation translates outcome estimates to patient lifetime event occurrence in the setting of heart valve diseaseMaximiliaan L Notenboom, Reda Rhellab, Jonathan R G Etnel, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 30, 2018
Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity†Simone A Huygens, Frank van der Kley, Jos A Bekkers, et al.
Pageof 2